
Abandon High‑Deductible Health Plans Linked to Health Spending Accounts | Jeanne Lambrew
The Health Affairs podcast episode focuses on Jeanne Lambrew’s argument to abandon, rather than expand, high‑deductible health plans (HDHPs) paired with health spending accounts. Lambrew traces the policy’s origins to 1990s conservative think‑tanks, noting three legislative boosts—the 2003 Medicare Modernization Act, the ACA’s clarification, and the recent One Big Beautiful Bill—that have entrenched HDHPs with health savings or flexible spending accounts in the market. Lambrew highlights that average deductibles have climbed to about $1,900 for employer‑based coverage and $2,800 for individual plans, while only one‑third of workers with employer insurance possess a spending account. She stresses that most health spending is driven by a small, sick population—20% of dollars go to the sickest patients—and that high deductibles act as a surcharge for those with pre‑existing conditions. Moreover, research shows HDHPs do not spur meaningful price shopping; utilization drops across the board, and accounts have negligible impact on total spending, sometimes prompting unnecessary purchases to avoid forfeiting balances. Key examples include the administration’s push to expand catastrophic plans with $31,000 family deductibles and a surge from 2% to 43% of marketplace enrollees selecting plans eligible for health savings accounts. Lambrew also cites the president’s “Great American Health Plan” rhetoric, which frames shifting cost burdens to consumers as the primary solution, despite evidence that such shifts increase out‑of‑pocket strain without lowering prices. The discussion concludes that without stronger government involvement—such as eliminating deductibles in ACA marketplace gold and silver plans or linking premium tax credits to higher‑value coverage—high‑deductible structures will exacerbate affordability challenges. State‑level experiments may provide a natural laboratory to assess whether expanding HDHPs with spending accounts truly improves cost transparency or merely deepens consumer financial risk.

Why Medicare Advantage Enrollees Are Leaving Plans
The Health Affairs podcast episode examines a new study on rapid disenrollment from Medicare Advantage (MA) plans, finding that the share of beneficiaries leaving a newly chosen plan within three months jumped from 3.5% in 2017 to 12.2% in 2022. The...

Medicare Drug Price Negotiation: What Can We Learn From the 2027 Prices and Their Justifications?
The webinar examined the Inflation Reduction Act’s new Medicare drug‑price negotiation program, focusing on the Centers for Medicare & Medicaid Services’ (CMS) recently published explanations for the 2027 maximum fair prices (MFPs). These explanations, released before the March 1 deadline, detail...

Innovation, Consumers, and How We Get to Better Health Care | Halle Tecco
The podcast features Holly Tecco discussing her new book Massively Better Healthcare, a guide for innovators tackling the system’s biggest challenges. Tecco frames the conversation around why “innovation” – not merely entrepreneurship – matters for anyone seeking to improve health outcomes, from...

The 2-Year Medicare Wait That Can Cost Lives
The podcast examines the two‑year Medicare enrollment lag imposed on Social Security Disability Insurance (SSDI) recipients and its stark health consequences. Dr. David Powell explains that the waiting period, created in 1972 to curb costs, leaves newly disabled workers without...

Medicare Advantage Payment & Coding Fights Intensify
The Health Affairs podcast episode focused on the escalating dispute over Medicare Advantage (MA) payments and the role of diagnostic coding intensity. Host Jeff Buyers and AEI scholar Ben Epilo explained that the federal government spends roughly 14% more on...

The Future of Heart Disease Diagnosis with AI
The podcast examines a new Health Affairs paper by Dr. Anna Zinc on the real‑world impact of an AI‑driven diagnostic tool, computed‑tomography fractional flow reserve (FFRCT), used alongside cardiac CT imaging. The discussion frames the study within the broader regulatory...

FDA & Rare Disease Drugs: Why Policy and Politics Are Heating Up
The episode focuses on the FDA’s new draft guidance designed to streamline approval pathways for ultra‑rare, often single‑patient, therapies. Host Jeff Buyers and guest Leslie Erlac discuss the policy shift against the backdrop of recent leadership turmoil, notably the departure...

Rethinking Longevity, Wellness & Aging | Zeke Emanuel
Zeke Emanuel, a physician and health-policy veteran, has published Eat Your Ice Cream: Six Simple Rules for a Long and Healthy Life, shifting his focus from system-level reform to practical, evidence-based advice for patients. Drawing on frustration with hype from...

State of the Union Healthcare Policy Breakdown
The latest State of the Union address featured a surprisingly detailed health‑policy segment, with President Trump urging Congress to codify a Most‑Favored‑Nation (MFN) or reference‑pricing framework for prescription drugs. The proposal would tie U.S. drug prices to those paid in...

Is Optum Reshaping Healthcare? What It Means for Prices & Referrals
The Health Affairs paper discussed on the podcast examines UnitedHealth’s Optum unit and its aggressive vertical integration strategy—specifically, the acquisition of physician practices and ambulatory surgical centers (ASCs). By linking insurer, provider, and pharmacy functions, Optum aims to capture...

Is Value-Based Payment Failing U.S. Healthcare? | Andrew Ryan
In a Health Affairs interview, Brown University researcher Andrew Ryan critiques the promise of value‑based payment (VBP) as a solution to Medicare’s affordability crisis. Drawing on a recent article he co‑authored, Ryan argues that empirical evidence—particularly a Congressional Budget Office...

The Surprising Impact of Drug Price Negotiation on Clinical Trials
The podcast examines a new Health Affairs paper that tracks how the Inflation Reduction Act’s Medicare drug‑price negotiation provision has affected biopharmaceutical clinical‑trial activity. Dr. So Young Kang and co‑authors compare industry‑sponsored trial initiations from 2015‑2024, focusing on firms directly hit...

The Medicaid ‘Ghost Doctor’ Problem Explained (Jane Zhu)
The podcast examines a new Health Affairs study led by Dr. Jane Zhu that uncovers a hidden "ghost doctor" problem in Medicaid. While 70‑90% of physicians across specialties are formally enrolled as Medicaid providers, a substantial share never treat Medicaid...

Sweeping Affordable Care Act Changes Proposed for 2027 (Katie Keith)
The Health Affairs podcast aired on February 13, 2026, unpacked a sweeping 577‑page proposed rule that would reshape the Affordable Care Act for the 2027 coverage year. Released unusually late in the rule‑making cycle, the proposal gives stakeholders just weeks...

2025 Dietary Guidelines: Protein, Policy, and the Ultra-Processed Foods Problem
The Health Affairs interview dissects the 2025 U.S. Dietary Guidelines, which notably prioritize protein, tighten language around ultra‑processed foods, and soften alcohol recommendations. Host Jeff Buyers and registered dietitian Jenny Low examine how these shifts diverge from previous guidance and...

Surviving the Hospital, Then the Bills
The Health Affairs study led by Dr. John W. Scott examines how acute traumatic injuries translate into heightened medical debt and bankruptcy risk. Using a unique linkage of credit‑bureau data with a state‑wide trauma registry, the researchers tracked patients before...